Cancer specialist goes for a dual listing
Saturday 03 July 2004
Cyclacel, the Scottish biotech company, yesterday became the latest healthcare group to reveal plans to float on Nasdaq and the London Stock Exchange.
The company, which specialises in pioneering cancer treatments, is planning to offer 16 million shares - about 26 per cent of the business - at an indicative price range of between 152p and 182p. This would give Cyclacel a market capitalisation of £91m.
Spiro Rombotis, the chief executive of Cyclacel, said the company was in a race to get its treatments to the market before larger pharmaceutical rivals. "We have the chance to be first to market in a massively important cancer field after Aventis unexpectedly terminated its development of a similar class of drug," Mr Rombotis said. He expects Cyclacel's lead drug, which treats a rare form of blood cancer, to reach the market as early as 2006.
"We have the opportunity to raise new funds when investors can see daylight in our plans.
"Without capital raising it would have been difficult to continue funding the pipeline and investing in the business," he said.
Mr Rombotis and the rest of the management team hold a 13 per cent stake in the business, which will be worth £14m when the company floats. The rest of the share capital is held by about 40 investors from across the globe. All existing shareholders are holding on to their holdings.
Cyclacel had considered floating in 2003, but was put off by weak equity markets and poor sentiment towards new listings. Its decision to float now follows a trend of biotech companies returning to the market.
Not all have been very successful, however. Ark Therapeutics floated in March, but the shares are trading well below its listing price. Norwood Immunology, the new vehicle for Rolf Stahel, formerly of Shire Pharmaceuticals, halved its valuation to £50m.
Diving in at the deep end is no excuse for shirking the style stakes
- 1 Why I'm on the brink of burning my Israeli passport
- 2 War is war: Why I stand with Israel
- 3 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 4 World Cup 2014: Robin van Persie appears to give his bronze medal to eccentric Netherlands fan moments after being handed it by Sepp Blatter
- 5 Iraq crisis: How Saudi Arabia helped Isis take over the north of the country
Ian Thorpe gay: Olympic swimmer comes out in Parkinson interview
Death in the Valley of the Dolls: Heroin overdose turns the spotlight on prostitution boom in California's tech industry
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Woman, 61, jailed for seven years after drink-drive death of cyclist
Gaza-Israel conflict: Pro-Palestinian demonstrators take to streets of London, Paris and New York in wave of protests
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...